Correction to "Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity"

ACS Pharmacol Transl Sci. 2024 Mar 6;7(4):1195-1196. doi: 10.1021/acsptsci.4c00095. eCollection 2024 Apr 12.

¹ Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry and Tübingen Center for Academic Drug Discovery, Eberhard Karls University Tübingen, Auf der Morgenstelle 8, Tübingen 72076, Germany.
² PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, Bonn 53121, Germany.
³ Infection Biology Unit, German Primate Center, Leibniz Institute for Primate Research Göttingen, Kellnerweg 4, Göttingen 37077, Germany.
⁴ Institute of Pharmacy, Pharmaceutical (Bio-)Analysis, Eberhard Karls University Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany.
⁵ Faculty of Biology and Psychology, University Göttingen, Göttingen 37073, Germany.
⁶ Faculty of Health Sciences, School of Pharmacy, University of Eastern Finland, Kuopio 70211, Finland.
⁷ Excellence Cluster "Controlling Microbes to Fight Infections" (CMFI), Tübingen 72076, Germany.
⁸ Department of Chemical Biology, Helmholtz Centre for Infection Research (HZI), Braunschweig 38124, Germany.
⁹ Partner Site Hannover-Braunschweig, German Center for Infection Research (DZIF), Braunschweig 38124, Germany.

Abstract

[This corrects the article DOI: 10.1021/acsptsci.3c00313.].